Toripalimab in combination with HBM4003, an anti-CTLA-4 heavy chain-only antibody, in advanced melanoma and other solid tumors: an open-label phase I trial

MLA

Michael Lee, et al. “Toripalimab in Combination with HBM4003, an Anti-CTLA-4 Heavy Chain-Only Antibody, in Advanced Melanoma and Other Solid Tumors: An Open-Label Phase I Trial.” Journal for ImmunoTherapy of Cancer, vol. 12, no. 10, Oct. 2024. EBSCOhost, https://doi.org/10.1136/jitc-2024-009662.

APA

Michael Lee, Jing Chen, Li Yao, Yu Chen, Yu Jiang, Feng Li, Xiubao Ren, Jun Guo, Bixia Tang, Chuanliang Cui, Gang Huang, Shuai Zhao, Zhihong Chi, Meng Qi, Xiaolu Tao, Quanli Gao, Xiaoshi Zhang, Meiyu Fang, Fei Zheng, … Rong Duan. (2024). Toripalimab in combination with HBM4003, an anti-CTLA-4 heavy chain-only antibody, in advanced melanoma and other solid tumors: an open-label phase I trial. Journal for ImmunoTherapy of Cancer, 12(10). https://doi.org/10.1136/jitc-2024-009662

Chicago

Michael Lee, Jing Chen, Li Yao, Yu Chen, Yu Jiang, Feng Li, Xiubao Ren, et al. 2024. “Toripalimab in Combination with HBM4003, an Anti-CTLA-4 Heavy Chain-Only Antibody, in Advanced Melanoma and Other Solid Tumors: An Open-Label Phase I Trial.” Journal for ImmunoTherapy of Cancer 12 (10). doi:10.1136/jitc-2024-009662.